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Abstract
Bovine respiratory syncytial virus (BRSV) is an etiological component of the bovine respiratory tract disease complex. Infection
with BRSV following vaccination, or re-infection following natural infection is common since protection is incomplete. The objectives of this study were to create plasmid DNA constructs encoding single or multiple N-glycosylation-site deletion BRSV fusion (F) proteins, and evaluate their expression in cell culture, and potential to induce anti-BRSV F antibody responses in BALB/
c mice. Four plasmid DNAs were constructed, each encoding 1-4 N-glycosylation-site deletions: Gly4, Gly2/4, Gly1/2/4 and
Gly1/2/3/4. Each of the N-glycosylation-site deletion BRSV F proteins were expressed in COS-7 cells following transfection with
plasmid DNA. Inoculation of BALB/c mice with plasmid DNA, resulted in a significant anti-BRSV F IgG response to the wildtype (WT) F and glycosylation-site deletion protein Gly2/4. Gly2/4 elicited a higher antibody titer than the fully glycosylated WT
F protein. Significant neutralizing antibody titers were detected following immunization with the Gly2/4 plasmid DNA. These
glycosylation-site deletion BRSV F proteins will be useful to characterize the effects of glycosylation on immunogenicity in the
natural host, and may lead to a new approach for the generation of BRSV vaccines.
Keywords: Bovine respiratory syncytial virus, Fusion protein, Glycosylation

mice with the F protein elicits protective cytotoxic T lymphocyte (CTL) and T-helper (TH) cell responses [5].
The BRSV F glycoprotein is a type I envelope glycoprotein which plays an important role in fusion of the
viral envelope to the host cell membrane. The F protein
causes infected cells to fuse to adjacent cells, forming syncytia, or multi-nucleated cells [6]. The F protein is synthesized as an inactive precursor, F0, which is then cleaved
to form two disulfide-linked subunits, F1 and F2 [7]. The F
protein is post-translationally modified by cleavage, folding and glycosylation before being transported to the cell
surface [8]. Depending on the BRSV strain, the F protein
may have either three or four N-glycosylation sites. Two

1. Introduction
Bovine respiratory syncytial virus (BRSV) is a primary
cause of lower respiratory tract disease in calves and is
an etiological component of the bovine respiratory disease complex [1]. BRSV is a member of the genus Pneumovirus in the family Paramyxoviridae [2]. Infection with
BRSV following vaccination, or re-infection following
natural infection is common since protection is incomplete [3]. The attachment (G) and fusion (F) surface glycoproteins are the most immunogenic in humoral immunity
[4]. Monoclonal antibodies to the G or F protein protect
against lower respiratory tract infection [4]. Priming of
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or three sites are located on the F2 subunit, while one site
is located on the F1 subunit [9, 10]. Glycosylation is an important modification that can affect the folding, transport,
and immunogenicity of proteins [11].
Carbohydrate moieties on surface glycoproteins, such
as the F protein, may modulate immunogenicity of the
protein. Glycans can shield large regions of the protein
surface, providing protection from proteases and masking epitopes. It is also possible that the removal of carbohydrates cause a shift in the conformation of the polypeptide backbone, altering the recognition of immunogenic
epitopes [12]. Palomo et al. [13], showed that removal of
carbohydrates on the G protein of human respiratory syncytial virus (HRSV) reduced recognition by monoclonal
antibodies (MAbs). Of the 18 MAbs that originally recognized the fully O- and N-glycosylated protein, only five
MAbs recognized the unglycosylated G protein. In this
case, the carbohydrates comprised the epitope, or were
necessary for recognition of the epitope by the MAbs [13].
Completely effective vaccines for both HRSV and
BRSV are yet to be developed. Previously, a formalin-inactivated (FI) HRSV vaccine was used which exacerbated
illness in vaccinated children following natural exposure
to the virus [14]. Vaccine-enhanced respiratory disease
has also been reported in calves using an experimental FIBRSV vaccine [15]. A number of approaches have been explored to develop a more effective vaccine. One approach
has been the development of DNA vaccines, which have
advantages over the live- or FI-vaccines. DNA vaccines
are safer, more cost-effective and can be manipulated to
alter the qualitative and quantitative humoral and cellular immune responses [16].
Plasmid DNA vaccines encoding the G and F proteins
of HRSV have been effective in inducing neutralizing antibodies. Intramuscular inoculation with plasmid DNA
encoding the F glycoprotein resulted in high neutralizing antibody titers, protection against live challenge and
production of interferon-γ and CD8+ CTLs [17]. The immunization of mice with plasmid DNA encoding the fulllength and secreted HRSV G resulted in a balanced Th1/
Th2 response following virus challenge [17]. The objectives of this study were to create plasmid DNA constructs
encoding WT and N-linked glycosylation-site deletion
BRSV F proteins and to characterize expression in cell
culture and induction of antibody responses in BALB/c
mice.

in a 37 °C humidified chamber with 5% CO2. Confluent
monolayers were infected with BRSV strain 375 at a multiplicity of infection (m.o.i.) of 0.01 in tissue culture flasks.
Inoculated cell cultures were maintained at 33 °C in a humidified chamber with 5% CO2 (~2 weeks) until the cells
developed 50% cytopathic effect (CPE). Cells were frozen
at −80 °C, thawed, dispensed into aliquots, then frozen
again at −80 °C until used. Recombinant vaccinia virus
expressing T7 polymerase (vvT7) was kindly provided by
Dr. Bernard Moss (National Institute of Health, Bethesda,
MD).

2. Materials and methods

2.3. Construction of N-glycosylation-site deletion BRSV F
proteins

2.1. Cells and viruses
Bovine turbinate (BT) cells (National Veterinary Services Laboratory, Ames, IA) and African green monkey
kidney (COS-7) cells (American Type Culture Collection, CRL-1651, Rockville, MD) were grown in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with
10% equine serum (Hyclone, Logan, UT) and maintained

2.2. Construction of plasmid DNA vector encoding the wildtype BRSV F glycoprotein
Viral RNA was isolated from BRSV-infected BT cells
using TRIZOL LS reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. The 1800 bp
BRSV F glycoprotein cDNA sequence was generated from
total RNA using Superscript II reverse transcriptase (Invitrogen) and the primer F2, 5′-GGATCCAAAAATGCAGGTCTTGGCGGATAC-3′, complementary to nucleotide
base numbers 1801–1824 of the BRSV 375 F glycoprotein,
with a BamHI restriction site incorporated (underlined).
The BRSV F cDNA was amplified using Taq polymerase
(Invitrogen), with primers F2 and F1, 5′-GGATCCATAAGGATGGCGGCAACAGC-3′, corresponding to nucleotide base numbers 1–14 of BRSV F. The BRSV F specific
primers were purchased from Sigma Genosys (Woodlands, TX). The reaction mixture was denatured at 94 °C
for 1 min, annealed at 50 °C for 1 min and extended at
72 °C for 2 min for a total of 30 cycles, followed by an additional extension of 7 min at 72 °C.
The BRSV F PCR product was gel purified (QIAEX
II Gel Extraction Kit, QIAGEN, Valencia, CA) and subcloned into the pCR 2.1 vector using the TA Cloning Kit
(Invitrogen). The BRSV F cDNA was excised from the
pCR 2.1 vector using restriction enzymes SpeI and NotI,
and ligated using T4 DNA ligase into the mammalian expression vector, pcDNA 3.1/His (Invitrogen), previously
digested with NotI and XbaI, creating the construct 3.1/
His/F. This placed the BRSV F cDNA downstream of the
T7 RNA polymerase and upstream of the bovine growth
hormone polyadenylation signal sequence. DNA sequencing (DNA Sequencing Facility, Iowa State University, Ames, IA) was performed after cloning to confirm
the insert was in the proper reading frame.

The N-glycosylation deletion BRSV F protein coding
regions were generated by replacing the asparagine triplet (AAC) at positions N27, N70, N120 and N500 of the
3.1/His/F cDNA with the alanine triplet (GCC) using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA) according to the manufacturer’s instructions.
Site-directed mutagenesis was performed using Pfu-
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Figure 1. Glycosylation-site specific primers used to make BRSV F N-glycosylation-site deletion proteins for DNA inoculation of
BALB/c mice. The double nucleotide change is underlined. The first two nucleotides of the triplet codons were changed to exchange the asparagine triplet codon (AAC) with an alanine triplet codon (GCC) to create plasmid DNA encoding N-glycosylationsite deletion proteins: Gly4, Gly2/4, Gly1/2/4 and Gly1/2/3/4.

Turbo™ DNA polymerase, and glycosylation-site specific
primers (Figure 1). BRSV F N-glycosylation-site specific
primers containing the two nucleotide changes were purchased from Sigma Genosys (Woodlands, TX). The reaction mixture was denatured at 95 °C for 30 s, annealed at
55 °C for 1 min and extended at 68 °C for 14 min, for a total of 16 cycles. Following temperature cycling, the product was treated with DpnI endonuclease at 37 °C for 1 h to
digest the parental DNA. The PCR-synthesized plasmid
DNA was then transformed into XL-1 Blue Supercompetent Cells (Stratagene). Ampicillin-resistant colonies were
selected and plasmid DNA extracted using the Wizard
Plus Mini-Prep Kit (Promega) according to the manufacturer’s instructions. The nucleotide exchanges were confirmed by DNA sequencing. Plasmid DNA encoding the
glycosylation-site deletion proteins was identified according to the deleted glycosylation-site(s) (i.e. Gly2/4 had the
second and fourth N-glycosylation-sites deleted).
2.4. Expression of BRSV F N-glycosylation-site deletion proteins in mammalian cells
Expression of the WT and N-glycosylation-site deletion BRSV F proteins was evaluated in COS-7 cells following transfection using a vaccinia virus-T7 RNA polymerase expression system [18]. Following infection with
T7-vaccinia virus, COS-7 cells were transfected with plasmid DNA using a cationic lipid-mediated method (LipofectAMINE 2000 Reagent, Invitrogen) according to the
manufacturer’s instructions.

Twenty-four hours following transfection, the COS7 cells were fixed with 20% acetone (v/v) in phosphatebuffered saline (PBS). The BRSV F protein was detected
using an immunoperoxidase staining protocol [19] with
MAb 8G12, specific for BRSV F, as the primary antibody
and biotinylated horse anti-mouse IgG (H + L) (Vector
Laboratories, Burlingame, CA) as the secondary antibody.
Antibody binding was detected using streptavidin horseradish peroxidase conjugate (Zymed, San Francisco, CA)
and 3-amino-9-ethyl-carbazole substrate (AEC, Sigma, St.
Louis, MO). Additionally, cells were transfected and lysed
with 0.5% NP-40 lysis buffer, then proteins separated by
discontinuous SDS-PAGE electrophoresis. The separated
proteins were transferred onto a nitrocellulose membrane
and non-specific sites blocked by incubation with PBS, pH
7.6, containing 5% nonfat dry milk. The membrane was
then incubated with the primary antibody, MAb 8G12
(1:1000), followed by alkaline phosphatase-labeled goat
anti-mouse IgG (H + L) (KPL, Gaithersburg, MD) as the
secondary antibody. Antibody binding was detected using 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium substrate (KPL, Gaithersburg, MD).
2.5. DNA inoculation of BALB/c mice
Prior to initiation of the experiments, this project was
reviewed and approved by the University of Nebraska Institutional Animal Care and Use Committee to ensure humane use and treatment of animals, and guidelines were
adhered to throughout the course of the study. Plasmid
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DNA encoding the WT F and the N-glycosylation-site
deletion proteins was purified using a plasmid Mega kit
from QIAGEN according to the manufacturer’s instructions. The purified DNA pellet was resuspended in 0.89%
NaCl. Seven-week-old female, specific pathogen-free
BALB/c mice, purchased from Charles River Laboratories
(Wilmington, MA), were housed in BL-2 rooms at the Animal Research Facility, University of Nebraska-Lincoln.
The mice were assigned to one of seven treatment
groups: (1) pcDNA 3.1/His encoding the fully glycosylated BRSV F protein (WT F), (2) pcDNA 3.1/His encoding a single glycosylation-site deletion protein (Gly4), (3)
pcDNA 3.1/His encoding a double glycosylation-site deletion protein (Gly2/4), (4) pcDNA 3.1/His encoding a
triple glycosylation-site deletion protein (Gly1/2/4), (5)
pcDNA 3.1/His encoding a quadruple glycosylation-site
deletion protein (Gly1/2/3/4), (6) live BRSV virus, or (7)
no treatment. Each treatment group was comprised of
four or five mice. Mice were inoculated in the rectus femoris muscle with 100 μg of plasmid DNA. Booster inoculations were given at 4 and 8 weeks, by the same route and
with the same dose of plasmid DNA. Three weeks following the final inoculation (day 78), all mice were anesthetized by injecting intramuscularly (IM) with 40 μg/g
ketamine and 6 μg/g Xylazine and bled by cardiac puncture. An equal amount of Alsever’s solution was added
to the blood. The mice were then euthanatized by CO2
inhalation.
2.6. Antibody responses in mice following plasmid DNA
inoculation
Plasma was analyzed for anti-BRSV F antibodies using
an indirect enzyme-linked immunosorbent assay (ELISA),
with modifications [20]. BT cells infected with BRSV using an m.o.i. of 0.1 were used as antigen and propagated
in 96-well microtiter plates. Following incubation for 4
days, cells were fixed with 20% acetone in PBS (v/v). Infected cells were blocked with 1% bovine serum albumin
(BSA) in PBS with 0.15% Tween for 1 h at 37 °C. Two-fold
dilutions (1:10–1:1280) of mouse plasma were prepared,
added to the cells and incubated for 1 h at 37 °C. Cells
were then incubated with alkaline phosphatase-labeled
goat anti-mouse IgG (H + L) (KPL, Gaithersburg, MD),
diluted 1:1000 in 0.1% BSA in PBS-Tween, for 1 h at 37 °C.
The substrate, p-nitrophenyl phosphate, was then added,
incubated at room temperature for 30 min and the optical
density (OD) values were determined using a microplate
reader (MR 700, Dynatech Laboratories) at 410 nm.
Neutralizing antibody titers were determined by combining serial two-fold dilutions (1:2–1:256) of heat-inactivated (56 °C for 30 min) plasma with BRSV (150 TCID50/
50 μl) in 96-well microtiter plates for 1 h at 37 °C with 5%
CO2. Following incubation, 1 × 105 BT cells were added to
each well and incubated 5 days at 37 °C. Cells were examined microscopically for viral CPE and then fixed with
20% acetone in PBS (v/v). Plates were stained with an immunoperoxidase staining assay [19] and virus neutraliz-
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ing antibody titers were determined as the highest plasma
dilution inhibiting BRSV CPE.
2.7. Statistical analysis
Results in the different treatment groups of mice for
both the ELISA and neutralization assays were compared and analyzed statistically using analysis of variance [21]. ELISA antibody and virus neutralizing antibody titers for each treatment group were compared to
all other treatment groups to identify difference between
treatments. P values of <0.05 were considered to be statistically significant.
3. Results
3.1. Plasmid DNA vectors encoding BRSV F N-glycosylationsite deletion proteins
The plasmids encoding the WT and each of the four
BRSV F N-glycosylation deletion proteins for DNA inoculation were constructed and DNA sequencing confirmed
that the specific asparagine triplet(s) were replaced with
alanine triplet(s) for each of the glycosylation-site deletion plasmids, as well as in the proper reading frame. The
vectors encoded: (1) WT BRSV F protein; (2) BRSV F Gly4
protein (deletion of N500); (3) BRSV F Gly2/4 protein (deletion of N70 and N500); (4) BRSV F Gly1/2/4 protein (deletion of N27, N70 and N500) or (5) BRSV F Gly1/2/3/4
protein (deletion of N27, N70, N120 and N500) (Figure 2).
Using a T7-vaccinia virus expression system, transcription was under control of the T7 promoter.
3.2. COS-7 cells express the BRSV F N-glycosylation-site
deletion proteins
Expression of the F proteins was evaluated using an immunoperoxidase assay. Cytoplasmic staining was detected
in the COS-7 cells transfected with each of the plasmid

Figure 2. Schematic drawing of the plasmid DNAs encoding
the wild-type (WT) and N-glycosylation-site deletion BRSV F
proteins Gly4, Gly2/4, Gly1/2/4, and Gly1/2/3/4 constructed
using site-directed mutagenesis. Arrows illustrate the location of the N-glycans. The fully glycosylated WT F has N-glycans located at asparagine residues 27, 70, 120 and 500. Each
plasmid DNA encoding a different glycosylation-site deletion
protein was named according to the specific N-glycan site(s)
deleted.
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Figure 3. Cytoplasmic staining using an immunoperoxidase assay in COS-7 cells transiently transfected with plasmid DNA encoding the WT and N-glycosylation-site deletion BRSV F proteins. (A) COS-7 cells transfected with the pcDNA 3.1 backbone, (B) COS7 cells transfected with DNA encoding the WT F protein. COS-7 cells transfected with DNA encoding the glycosylation-site deletion
mutants, (C) Gly4, (D) Gly2/4, (E) Gly1/2/4 and (F) Gly1/2/3/4 mutant. Expression of the F protein was detected using MAb 8G12.

DNAs encoding the N-glycosylation-site deletion BRSV F
proteins (Figure 3). The staining intensity of cells transfected with each plasmid DNA construct was comparable
to staining of cells transfected with the WT F. No staining
was observed in the negative control, COS-7 cells transfected with the plasmid pcDNA 3.1 backbone.
Cell lysates were collected from COS-7 cells transfected with plasmid DNA encoding the BRSV F WT and
N-glycosylation-site deletion proteins. Western blot analyses showed that each N-glycosylation-site deletion protein and the WT F protein resolved as a 68 kDa band, with
the F1 subunit resolving as a faint 48 kDa band (data not
shown).

plasmid DNA encoding the BRSV F N-glycosylation-site
deletion proteins had mean ELISA antibody titers that
ranged from <1:10 to 1:56 (Table 1). Plasma from mice immunized IM with live BRSV was used as a positive control for the ELISA. Plasma collected from these mice had
a mean BRSV F-specific antibody titer of 1:80. Inoculation
with plasmid DNA encoding the WT F and Gly2/4 resulted in development of significant (P < 0.05) BRSV antibody titers. Mice in the WT F and Gly2/4 groups had
mean antibody titers of 1:34 and 1:56, respectively. The
mice inoculated with Gly4, Gly1/2/4, Gly1/2/3/4 and
the negative control group (no treatment) did not develop
a significant antibody response.

3.3. BRSV F antibody response of BALB/c mice following plasmid DNA inoculation
To evaluate the IgG antibody response, plasma samples from mice immunized with plasmid DNA encoding
the BRSV F N-glycosylation-site deletion proteins were
analyzed using an indirect ELISA using BRSV-infected BT
cells as antigen. Antibody titers were determined by the
endpoint at which the OD410 nm given by the post-inoculation plasma was higher than the pre-inoculation OD410 nm
at the corresponding dilution, plus two times the standard
deviation given by the pre-inoculation plasma. Also, the
OD410 nm values given by post-inoculation plasma were
divided by the OD410 nm values given by pre-inoculation
plasma at the corresponding dilution to determine the signal to noise (S:N) ratio (Figure 4). Plasma collected from
the pre-inoculation bleed and from weeks 2 and 6 did not
have a detectable antibody response (data not shown).
Plasma collected on day 78 from mice inoculated with the

Figure 4. Anti-BRSV F IgG antibody response in BALB/c mice
following inoculation with WT F, Gly4, Gly2/4, Gly1/2/4,
Gly1/2/3/4, live BRSV, or no treatment. An indirect ELISA
was used to evaluate the antibody responses to the plasmid
DNA encoding the BRSV F proteins. Signal to noise (S:N) ratios were calculated by dividing the OD410 nm given by the
post-inoculation plasma by the OD410 nm given by the pre-inoculation plasma at the corresponding dilution.
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Table 1. Anti-BRSV IgG antibody responses in BALB/c mice
following inoculation with WT F, glycosylation-site deletion
constructs: Gly4, Gly2/4, Gly1/2/4 and Gly1/2/3/4; live
BRSV; or no treatment
Group

ELISA antibody titersa Neutralizing antibody titersb

Live BRSV
WT F
Gly4
Gly2/4
Gly1/2/4
Gly1/2/3/4
Negative

1:80A
1:34A,B
1:20B,C
1:56A
1:10B,C
<1:10C
<1:10C

1:128A
1:25B,C
1:20B,C
1:34B
<1:10C
<1:10C
<1:10C

a The mean endpoint antibody titers were determined by the last
dilution in which the post-inoculation OD410 was higher than the preinoculation OD410 plus two-times the standard deviation. Titers that
have no common letters are significantly different (P < 0.05).
b Mean neutralizing antibody titers were determined at 100% viral inhibition by immunoperoxidase staining. Titers that have no common letters are significantly different (P < 0.05).

Plasma was also analyzed for virus neutralizing antibodies against BRSV. Plasma collected on day 78 from
mice inoculated with the plasmid DNA encoding the Nglycosylation-site deletion proteins had mean neutralizing antibody titers that ranged from <1:10 to 1:34 (Table
1). Of the four plasmid DNA constructs encoding N-glycosylation-site deletion(s) tested, only the Gly2/4 glycosylation-site deletion construct elicited development of significant (P < 0.05) BRSV neutralizing antibodies in mice. Mice
inoculated with WT F, Gly4, Gly1/2/4 and Gly1/2/3/4
plasmid DNA, along with the negative control group did
not develop significant (P < 0.05) BRSV neutralizing antibody responses. The positive control group, mice inoculated with live virus, developed a relatively high mean virus neutralizing titer of 1:128 (Table 1).
4. Discussion
To characterize the effects of the four N-glycans of
BRSV F protein on expression in cell culture and immunogenicity in BALB/c mice, four plasmid DNAs were
constructed, each encoding a protein with 1-4 N-glycosylation-site(s) deleted: Gly4, Gly2/4, Gly1/2/4 and
Gly1/2/3/4. The deletion mutants were constructed by
replacing the corresponding N-glycosylation-site(s) of
each plasmid DNA with an alanine codon, preventing Nlinked glycosylation at that site. The plasmid DNAs encoding the BRSV WT F and N-glycosylation-site deletion
proteins were transfected into COS-7 cells to evaluate protein expression and were inoculated into BALB/c mice to
evaluate their potential to induce antibody responses. To
our knowledge, this is the first report of a study comparing the effects of multiple N-glycosylation-site deletions
of the BRSV F protein on antibody response using plasmid DNA.
Analyses of expression of the N-glycosylation-site deletion proteins in transfected COS-7 cells by an immuno-
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peroxidase assay demonstrated that the protein expression among these constructs was comparable and similar
to that of the wild-type protein. Additionally, expression
of the plasmid DNA encoding BRSV F WT or N-glycosylation-site deletion proteins in COS-7 cells was evaluated by Western blot analyses. The F protein resolved as a
68 kDa band and the F1 subunit resolved as a faint 48 kDa
band in each cell lysate.
Antibody responses of mice inoculated with the plasmid DNA encoding the WT F or N-glycosylation-site deletion proteins were analyzed using an indirect ELISA and
virus neutralizing antibody assay. Among the BRSV N-glycosylation-site deletion protein groups, mice inoculated
with Gly2/4 developed the highest ELISA titer and were
the only group that developed a significant neutralizing titer. The Gly2/4 ELISA titers were greater than those elicited by the WT F protein. The increase in antibody response
in the Gly2/4 group may be attributed to the unmasking of
an epitope or to a conformational change in the protein exposing an epitope when both the second and fourth N-glycans are deleted, since the single deletion, Gly4, did not induce a significant antibody titer with either assay.
Removal of BRSV F N-glycans resulted in decreased
anti-BRSV F-specific antibody responses when BALB/
c mice were inoculated with three of the four N-glycosylation-site deletion constructs. Mice inoculated with
the single (Gly4), the triple (Gly1/2/4), and the quadruple (Gly1/2/3/4) N-glycosylation-site deletion constructs
did not develop significant ELISA or virus neutralizing
antibody titers compared to the negative control mice.
The selective deletion of certain glycans may result in a
change in the protein conformation, thereby changing epitope presentation. Complete removal of N-glycans may
also have inhibited the folding and transport of the protein to the cell surface, preventing exposure of the protein
to antigen presenting cells. This could explain why mice
inoculated with Gly1/2/3/4 did not develop measurable
antibody responses detectable by ELISA or neutralizing
antibody assays.
Similar observations were made with the G glycoprotein of HRSV [13]. The complete removal of the O- and
N-glycans resulted in only five of 18 MAbs recognizing
HRSV G protein, compared to the completely glycosylated protein, which was recognized by all 18 MAbs. These
findings showed that the O- and N-glycans were crucial
for antigenicity of the HRSV G glycoprotein [13].
Taken together, the results of this study demonstrate
that the expression and antibody recognition of BRSV F
protein epitopes are influenced by N-glycosylation. The
removal of three or four N-glycosylation-sites from the
BRSV F protein, Gly1/2/4 and Gly1/2/3/4, altered the
protein such that antibody recognition was abolished. The
absence of antibody response may be a result of a protein
conformational change affecting epitope recognition or
alteration in the transport of the protein to the cell surface. Certain glycans may also mask epitopes. The greater
mean ELISA antibody and virus neutralizing titers of
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Gly2/4 than those elicited by the WT F protein suggest
unmasking of an epitope. Similar results were observed
with the gp70 protein of Rauscher murine leukemia virus, where removal of carbohydrates from the protein improved reactivity to most MAbs [22]. Similarly, the introduction of a glycosylation-site at residue 63 of the 1969
influenza virus caused the virus to be unreactive with the
antibody specific for that residue, confirming that the addition of a glycosylation-site can mask epitopes and alter
reactivity of antibodies with a viral protein [23].
Bovine CD4+ T cell epitopes are distributed within
the F1 subunit (peptides 99 and 100) of the BRSV F protein [24]. Several of these regions, which were recognized
by the CD4+ T cells from calves, are adjacent to previously identified B cell epitopes [25]. The antigenic sites
for neutralizing MAbs to the HRSV F protein have also
been mapped, primarily to the F1 subunit [26–28]. One
region is near the C terminal-end of the cysteine-rich region and not far from the heptad repeat [27]. Other highly
conserved neutralizing epitopes have been mapped to
the amino-terminal third of the F1 subunit, near the proteolytic activation site [28]. The location of the individual
glycosylation-site on the F1 subunit could inhibit recognition of one or more antigenic sites. Also, the multiple glycans located on the F2 subunit may account for so few epitopes being mapped to this area.
In summary, glycosylation affects how the BRSV F protein elicits a humoral immune response. The Gly2/4 deletion protein elicited the greatest mean ELISA antibody
titer of the glycosylation-site deletion proteins tested,
which was greater than the mean titer elicited by the fully
glycosylated WT F. It was also the only glycosylation-site
deletion protein that elicited a significant virus neutralizing antibody titer. Gly4, Gly1/2/4 and Gly1/2/3/4 did
not elicit a significant ELISA or virus neutralizing antibody response. Continued studies using BRSV F glycosylation-site deletion proteins in the natural host to characterize the effects of glycosylation on immunogenicity may
lead to a new approach for generation of BRSV vaccines
[29].

5. G. Taylor, L. H. Thomas, S. G. Wyld, J. Furze, P. Sopp, and
C. J. Howard, Role of T-lymphocyte subsets in recovery
from respiratory syncytial virus infection in calves, J Virol
69 (1995), pp. 6658–6664.

References

16. S. Gurunathan, D. M. Klinman, and R. A. Seder, DNA vaccines: immunology, application, and optimization, Annu
Rev Immunol 18 (2000), pp. 927–974.

1. D. G. Bryson, M. S. McNulty, E. F. Logan, and P. F. Cush,
Respiratory syncytial pneumonia in young calves: clinical and pathologic findings, Am J Vet Res 44 (1983), pp.
1648–1688.
2. R. I. B. Francki, C. M. Fauquet, D. L. Knudson, and F. Brown,
Classification and nomenclature of viruses, Fifth Report of
the International Committee on Taxonomy of Viruses, SpringerVerlag, New York and Wien (1991).
3. J. C. Baker, J. A. Ellis, and E. G. Clark, Bovine respiratory
syncytial virus, Vet Clin North Am Food Anim Pract 13
(1997), pp. 425–454.
4. E. E. Walsh, J. J. Schlesinger, and M. W. Brandriss, Protection
from respiratory syncytial virus infection in cotton rats by
passive transfer of monoclonal antibodies, Inf Immunol 43
(1984), pp. 756–758.

6. E. E. Walsh and J. Hruska, Monoclonal antibodies to respiratory syncytial virus protein: identification of the fusion
protein, J Virol 47 (1989), pp. 171–177.
7. A. Sheid and P. W. Choppin, Two disulfide-linked polypeptide chains constitute the active F of paramyxoviruses, Virol 80 (1977), pp. 54–66.
8. P. L. Collins and G. Mottet, Post-translational processing
and oligomerization of the fusion glycoprotein of human respiratory syncytial virus, J Gen Virol 72 (1991), pp.
3095–3101.
9. R. A. Lerch, K. Anderson, V. L. Amann, and G. W. Wertz,
Nucleotide sequence of the bovine respiratory syncytial virus fusion protein of mRNA and expression from a recombinant vaccinia virus, Virol 181 (1991), pp. 118–131.
10. M. K. Pastey and S. K. Samal, Structure and sequence comparison of bovine respiratory syncytial virus fusion protein, Virus Res 29 (1993), pp. 195–202.
11. R. W. Doms, R. A. Lamb, J. K. Rose, and A. Helenius, Folding and assembly of viral membrane proteins, Virol 193
(1993), pp. 545–562.
12. P. M. Rudd, T. Elliott, P. Cresswell, I. A. Wilson, and R. A.
Dwek, Glycosylation and the immune system, Science 291
(2001), pp. 2370–2376.
13. C. Palomo, B. Garcia-Barreno, C. Penas, and J. A. Melero,
The G protein of human respiratory syncytial virus: significance of carbohydrate side-chains and the C-terminal end
to its antigenicity, J Gen Virol 72 (1991), pp. 669–675.
14. A. Z. Kapikain, R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart, An epidemiological study on altered clinical reactivity to respiratory syncytial (RS) virus
infection in children previously vaccinated with an inactivated RS virus vaccine, Am J Epidemiol 89 (1969), pp.
405–421.
15. L. J. Gershwin, E. S. Schelegle, R. A. Gunther, M. L. Anderson, A. R. Woolums, and D. R. Larochelle et al., A bovine model of vaccine enhanced respiratory syncytial virus
pathophysiology, Vaccine 16 (1998), pp. 1225–1236.

17. X. Li, S. Sambhara, C. X. Li, M. Ewasyshyn, M. Parrington,
and J. Caterini et al., Protection against respiratory syncytial virus infection by DNA immunization, J Exp Med 188
(1998), pp. 681–688.
18. T. R. Fuerst, E. G. Niles, F. W. Studier, and B. Moss, Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7
RNA polymerase, Proc Natl Acad Sci USA 83 (1986), pp.
8122–8126.
19. B. W. Brodersen and C. L. Kelling, Effect of concurrent experimentally induced bovine respiratory syncytial virus
and bovine viral diarrhea virus infection on respiratory
tract and enteric diseases in calves, Am J Vet Res 59 (1998),
pp. 1423–1430.

BRSV

g l y c a n s a n d i n v i t r o e x p r e ss i o n a n d a n t i b o d y r e s p o n s e s i n

BALB/ c

mice

3395

20. R. A. Tripp, D. Moore, L. Jones, W. Sullender, J. Winter,
and L. J. Anderson, Respiratory syncytial virus G and/or
SH protein alters Th1 cytokines, natural killer cells, and
neutrophils responding to pulmonary infection in BALB/
c mice, J Virol 73 (1999), pp. 7099–7107.

26. J. Arbiza, G. Taylor, J. A. Lopez, J. Furze, S. Wyld, and P.
Whyte et al., Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed
against the fusion glycoprotein of human respiratory syncytial virus, J Gen Virol 73 (1992), pp. 2225–2234.

21. Statistical Analysis System (SAS) Users Guide, Version 6,
SAS Institute Inc., Cary, NC (1996).

27. J. A. Lopez, R. Bustos, C. Orvell, M. Berios, J. Arbiza, and B.
Barcia-Barreno et al., Antigenic structure of human respiratory syncytial virus fusion glycoprotein, J Virol 72 (1998),
pp. 6922–6928.

22. S. Alexander and J. H. Elder, Carbohydrate dramatically
influences immune reactivity of antisera to viral glycoprotein antigens, Science 226 (1984), pp. 1328–1330.
23. J. J. Skehel, D. J. Stevens, R. S. Daniels, A. R. Douglas, M.
Knossow, and I. A. Wilson et al., A carbohydrate side chain
on hemagglutinins of Hong Kong influenza viruses inhibit
recognition by a monoclonal antibody, Proc Natl Acad Sci
USA 81 (1984), pp. 1779–1783.
24. M. H. Fogg, K.R. Parsons, L. H. Thomas, and G. Taylor,
Identification of CD4+ T cell epitopes on the fusion (F) and
attachment (G) proteins of bovine respiratory syncytial virus (BRSV), Vaccine 19 (2001), pp. 3226–3240.
25. J. P. Langedijk, R. H. Meloen, and J. T. van Oirschott, Identification of a conserved neutralizing site in the first heptad
repeat of the fusion protein of respiratory syncytial virus,
Arch Virol 67 (1993), pp. 1627–1637.

28. J. A. Lopez, C. Penas, B. Garcia-Barreno, J. A. Melero, and
A. Portela, Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial
virus, J Virol 64 (1990), pp. 927–930.
29. G. Zimmer, I. Trotz, and G. Hennler, N-glycans of F protein differentially affect fusion activity of human respiratory syncytial virus, J Virol 75 (2001), pp. 4744–4751.

